Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial
Objective The aim of this work was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in adults with episodic migraine. Methods We performed a randomized, double‐blind, placebo‐controlled trial with a 12‐week baseline period and 24‐week intervention period in 5...
Gespeichert in:
| Veröffentlicht in: | Annals of neurology 2015-12, Vol.78 (6), p.970-981 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 981 |
|---|---|
| container_issue | 6 |
| container_start_page | 970 |
| container_title | Annals of neurology |
| container_volume | 78 |
| creator | Buettner, Catherine Nir, Rony-Reuven Bertisch, Suzanne M. Bernstein, Carolyn Schain, Aaron Mittleman, Murray A. Burstein, Rami |
| description | Objective
The aim of this work was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in adults with episodic migraine.
Methods
We performed a randomized, double‐blind, placebo‐controlled trial with a 12‐week baseline period and 24‐week intervention period in 57 adults with episodic migraine. Participants were randomly assigned to simvastatin 20 mg tablets twice‐daily plus vitamin D3 1,000 international units capsules twice‐daily or matching placebo tablets and capsules.
Results
Compared to placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of migraine days from the baseline period to intervention weeks 1 to 12: a change of –8.0 (interquartile range [IQR]: −15.0 to −2.0) days in the active treatment group versus +1.0 (IQR: −1.0 to + 6.0) days in the placebo group, p |
| doi_str_mv | 10.1002/ana.24534 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4715556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760887557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5404-36edf4257794fd1ffa19d825fff16873030215f3932f60421b4b2d95a14ce9a03</originalsourceid><addsrcrecordid>eNqNkV1rFDEUhkNR2rX1wj8gAW8qOO3J94wXhbVqW1gqUj_Am5CdSWrqTLIms6v11xu77aKC4E0SyHMezjkvQo8IHBAAemiCOaBcML6FJkQwUtWUN_fQBJjklSCM76AHOV8BQCMJbKMdKjmpGScT9PbCDyuTRzP6gE3o8MqPZijvl9jFhAd_mYwPFi-SXdkw-hie4ylOhYyD_2G7Z7iNYUyx722Hx-RNv4fuO9Nn-_D23kXvX796d3xazd6cnB1PZ1UrOPCKSds5ToVSDXcdcc6QpqupcM4RWSsGDCgRjjWMOgmckjmf064RhvDWNgbYLjpaexfL-WC7tnSXTK8XyQ8mXetovP7zJ_jP-jKuNFdECCGLYP9WkOLXpc2jHnxubd-bYOMya6KUlJJzYP-BSqhrJYQq6JO_0Ku4TKFsolBCgYByFOrpmmpTzDlZt-mbgP6VqS6Z6ptMC_v490E35F2IBThcA998b6__bdLT8-mdslpX-Dza75sKk75oqZgS-uP5iZ59uChrUp_0C_YTMZO5GA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757050570</pqid></control><display><type>article</type><title>Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Buettner, Catherine ; Nir, Rony-Reuven ; Bertisch, Suzanne M. ; Bernstein, Carolyn ; Schain, Aaron ; Mittleman, Murray A. ; Burstein, Rami</creator><creatorcontrib>Buettner, Catherine ; Nir, Rony-Reuven ; Bertisch, Suzanne M. ; Bernstein, Carolyn ; Schain, Aaron ; Mittleman, Murray A. ; Burstein, Rami</creatorcontrib><description>Objective
The aim of this work was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in adults with episodic migraine.
Methods
We performed a randomized, double‐blind, placebo‐controlled trial with a 12‐week baseline period and 24‐week intervention period in 57 adults with episodic migraine. Participants were randomly assigned to simvastatin 20 mg tablets twice‐daily plus vitamin D3 1,000 international units capsules twice‐daily or matching placebo tablets and capsules.
Results
Compared to placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of migraine days from the baseline period to intervention weeks 1 to 12: a change of –8.0 (interquartile range [IQR]: −15.0 to −2.0) days in the active treatment group versus +1.0 (IQR: −1.0 to + 6.0) days in the placebo group, p < 0.001; and to intervention weeks 13 to 24: a change of −9.0 (IQR: −13 to −5) days in the active group versus +3.0 (IQR: −1.0 to + 5.0) days in the placebo group, p < 0.001. In the active treatment group, 8 patients (25%) experienced 50% reduction in the number of migraine days at 12 weeks and 9 (29%) at 24 weeks postrandomization. In comparison, only 1 patient (3%) in the placebo group (p = 0.03) experienced such a reduction. Adverse events were similar in both active treatment and placebo groups.
Interpretation
The results demonstrate that simvastatin plus vitamin D is effective for prevention of headache in adults with episodic migraine. Given statins' ability to repair endothelial dysfunction, this economical approach may also reduce the increased risk for vascular diseases among migraineurs. Ann Neurol 2015;78:970–981</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.24534</identifier><identifier>PMID: 26418341</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Cholecalciferol - administration & dosage ; Cholecalciferol - adverse effects ; Cholecalciferol - pharmacology ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Male ; Middle Aged ; Migraine ; Migraine Disorders - prevention & control ; Outcome Assessment (Health Care) ; Placebo effect ; Simvastatin - administration & dosage ; Simvastatin - adverse effects ; Simvastatin - pharmacology ; Vitamin D ; Young Adult</subject><ispartof>Annals of neurology, 2015-12, Vol.78 (6), p.970-981</ispartof><rights>2015 American Neurological Association</rights><rights>2015 American Neurological Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5404-36edf4257794fd1ffa19d825fff16873030215f3932f60421b4b2d95a14ce9a03</citedby><cites>FETCH-LOGICAL-c5404-36edf4257794fd1ffa19d825fff16873030215f3932f60421b4b2d95a14ce9a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.24534$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.24534$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26418341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buettner, Catherine</creatorcontrib><creatorcontrib>Nir, Rony-Reuven</creatorcontrib><creatorcontrib>Bertisch, Suzanne M.</creatorcontrib><creatorcontrib>Bernstein, Carolyn</creatorcontrib><creatorcontrib>Schain, Aaron</creatorcontrib><creatorcontrib>Mittleman, Murray A.</creatorcontrib><creatorcontrib>Burstein, Rami</creatorcontrib><title>Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Objective
The aim of this work was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in adults with episodic migraine.
Methods
We performed a randomized, double‐blind, placebo‐controlled trial with a 12‐week baseline period and 24‐week intervention period in 57 adults with episodic migraine. Participants were randomly assigned to simvastatin 20 mg tablets twice‐daily plus vitamin D3 1,000 international units capsules twice‐daily or matching placebo tablets and capsules.
Results
Compared to placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of migraine days from the baseline period to intervention weeks 1 to 12: a change of –8.0 (interquartile range [IQR]: −15.0 to −2.0) days in the active treatment group versus +1.0 (IQR: −1.0 to + 6.0) days in the placebo group, p < 0.001; and to intervention weeks 13 to 24: a change of −9.0 (IQR: −13 to −5) days in the active group versus +3.0 (IQR: −1.0 to + 5.0) days in the placebo group, p < 0.001. In the active treatment group, 8 patients (25%) experienced 50% reduction in the number of migraine days at 12 weeks and 9 (29%) at 24 weeks postrandomization. In comparison, only 1 patient (3%) in the placebo group (p = 0.03) experienced such a reduction. Adverse events were similar in both active treatment and placebo groups.
Interpretation
The results demonstrate that simvastatin plus vitamin D is effective for prevention of headache in adults with episodic migraine. Given statins' ability to repair endothelial dysfunction, this economical approach may also reduce the increased risk for vascular diseases among migraineurs. Ann Neurol 2015;78:970–981</description><subject>Adult</subject><subject>Cholecalciferol - administration & dosage</subject><subject>Cholecalciferol - adverse effects</subject><subject>Cholecalciferol - pharmacology</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Migraine Disorders - prevention & control</subject><subject>Outcome Assessment (Health Care)</subject><subject>Placebo effect</subject><subject>Simvastatin - administration & dosage</subject><subject>Simvastatin - adverse effects</subject><subject>Simvastatin - pharmacology</subject><subject>Vitamin D</subject><subject>Young Adult</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV1rFDEUhkNR2rX1wj8gAW8qOO3J94wXhbVqW1gqUj_Am5CdSWrqTLIms6v11xu77aKC4E0SyHMezjkvQo8IHBAAemiCOaBcML6FJkQwUtWUN_fQBJjklSCM76AHOV8BQCMJbKMdKjmpGScT9PbCDyuTRzP6gE3o8MqPZijvl9jFhAd_mYwPFi-SXdkw-hie4ylOhYyD_2G7Z7iNYUyx722Hx-RNv4fuO9Nn-_D23kXvX796d3xazd6cnB1PZ1UrOPCKSds5ToVSDXcdcc6QpqupcM4RWSsGDCgRjjWMOgmckjmf064RhvDWNgbYLjpaexfL-WC7tnSXTK8XyQ8mXetovP7zJ_jP-jKuNFdECCGLYP9WkOLXpc2jHnxubd-bYOMya6KUlJJzYP-BSqhrJYQq6JO_0Ku4TKFsolBCgYByFOrpmmpTzDlZt-mbgP6VqS6Z6ptMC_v490E35F2IBThcA998b6__bdLT8-mdslpX-Dza75sKk75oqZgS-uP5iZ59uChrUp_0C_YTMZO5GA</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Buettner, Catherine</creator><creator>Nir, Rony-Reuven</creator><creator>Bertisch, Suzanne M.</creator><creator>Bernstein, Carolyn</creator><creator>Schain, Aaron</creator><creator>Mittleman, Murray A.</creator><creator>Burstein, Rami</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201512</creationdate><title>Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial</title><author>Buettner, Catherine ; Nir, Rony-Reuven ; Bertisch, Suzanne M. ; Bernstein, Carolyn ; Schain, Aaron ; Mittleman, Murray A. ; Burstein, Rami</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5404-36edf4257794fd1ffa19d825fff16873030215f3932f60421b4b2d95a14ce9a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Cholecalciferol - administration & dosage</topic><topic>Cholecalciferol - adverse effects</topic><topic>Cholecalciferol - pharmacology</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Migraine Disorders - prevention & control</topic><topic>Outcome Assessment (Health Care)</topic><topic>Placebo effect</topic><topic>Simvastatin - administration & dosage</topic><topic>Simvastatin - adverse effects</topic><topic>Simvastatin - pharmacology</topic><topic>Vitamin D</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buettner, Catherine</creatorcontrib><creatorcontrib>Nir, Rony-Reuven</creatorcontrib><creatorcontrib>Bertisch, Suzanne M.</creatorcontrib><creatorcontrib>Bernstein, Carolyn</creatorcontrib><creatorcontrib>Schain, Aaron</creatorcontrib><creatorcontrib>Mittleman, Murray A.</creatorcontrib><creatorcontrib>Burstein, Rami</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buettner, Catherine</au><au>Nir, Rony-Reuven</au><au>Bertisch, Suzanne M.</au><au>Bernstein, Carolyn</au><au>Schain, Aaron</au><au>Mittleman, Murray A.</au><au>Burstein, Rami</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2015-12</date><risdate>2015</risdate><volume>78</volume><issue>6</issue><spage>970</spage><epage>981</epage><pages>970-981</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><abstract>Objective
The aim of this work was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in adults with episodic migraine.
Methods
We performed a randomized, double‐blind, placebo‐controlled trial with a 12‐week baseline period and 24‐week intervention period in 57 adults with episodic migraine. Participants were randomly assigned to simvastatin 20 mg tablets twice‐daily plus vitamin D3 1,000 international units capsules twice‐daily or matching placebo tablets and capsules.
Results
Compared to placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of migraine days from the baseline period to intervention weeks 1 to 12: a change of –8.0 (interquartile range [IQR]: −15.0 to −2.0) days in the active treatment group versus +1.0 (IQR: −1.0 to + 6.0) days in the placebo group, p < 0.001; and to intervention weeks 13 to 24: a change of −9.0 (IQR: −13 to −5) days in the active group versus +3.0 (IQR: −1.0 to + 5.0) days in the placebo group, p < 0.001. In the active treatment group, 8 patients (25%) experienced 50% reduction in the number of migraine days at 12 weeks and 9 (29%) at 24 weeks postrandomization. In comparison, only 1 patient (3%) in the placebo group (p = 0.03) experienced such a reduction. Adverse events were similar in both active treatment and placebo groups.
Interpretation
The results demonstrate that simvastatin plus vitamin D is effective for prevention of headache in adults with episodic migraine. Given statins' ability to repair endothelial dysfunction, this economical approach may also reduce the increased risk for vascular diseases among migraineurs. Ann Neurol 2015;78:970–981</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26418341</pmid><doi>10.1002/ana.24534</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-5134 |
| ispartof | Annals of neurology, 2015-12, Vol.78 (6), p.970-981 |
| issn | 0364-5134 1531-8249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4715556 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Cholecalciferol - administration & dosage Cholecalciferol - adverse effects Cholecalciferol - pharmacology Double-Blind Method Drug Therapy, Combination Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Male Middle Aged Migraine Migraine Disorders - prevention & control Outcome Assessment (Health Care) Placebo effect Simvastatin - administration & dosage Simvastatin - adverse effects Simvastatin - pharmacology Vitamin D Young Adult |
| title | Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T02%3A56%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simvastatin%20and%20vitamin%20D%20for%20migraine%20prevention:%20A%20randomized,%20controlled%20trial&rft.jtitle=Annals%20of%20neurology&rft.au=Buettner,%20Catherine&rft.date=2015-12&rft.volume=78&rft.issue=6&rft.spage=970&rft.epage=981&rft.pages=970-981&rft.issn=0364-5134&rft.eissn=1531-8249&rft_id=info:doi/10.1002/ana.24534&rft_dat=%3Cproquest_pubme%3E1760887557%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757050570&rft_id=info:pmid/26418341&rfr_iscdi=true |